A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants

Conditions

• Healthy Volunteer

Eligibility Criteria

Sex

ALL

Age

18 Years - 65 Years

Healthy Volunteers

Accepted

Interventions

• ABBV-859 — DRUG
  Oral Tablet
• Placebo for ABBV-859 — DRUG
  Oral Tablet
• ABBV-859 — DRUG
  Intravenous (IV) Infusion
• Placebo for ABBV-859 — DRUG
  Intravenous (IV) Infusion

Study Details

The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-859 after single ascending doses in healthy adult volunteers.

Key Dates

First listed

Jul 30, 2026

Start date

Jul 28, 2026

Status verified

Jul 2026

Primary completion

Feb 28, 2027

Completion

Feb 28, 2027

Study Design

Enrollment

64 participants (estimated)

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Group 1
  Participants will receive either ABBV-859 single Dose A, or the Placebo equivalent, on Study Day 1
• Experimental: Group 2
  Participants will receive either ABBV-859 single Dose B, or the Placebo equivalent, on Study Day 1
• Experimental: Group 3
  Participants will receive either ABBV-859 single Dose C, or the Placebo equivalent, on Study Day 1
• Experimental: Group 4
  Participants will receive either ABBV-859 single Dose D, or the Placebo equivalent, on Study Day 1
• Experimental: Group 5
  Participants will receive either ABBV-859 single Dose E, or the Placebo equivalent, on Study Day 1
• Experimental: Group 6
  Participants will receive either ABBV-859 single Dose F, or the Placebo equivalent, on Study Day 1
• Experimental: Group 7
  Participants will receive either ABBV-859 single Dose G, or the Placebo equivalent, on Study Day 1
• Experimental: Group 8
  Participants will receive either ABBV-859 single Dose H, or the Placebo equivalent, on Study Day 1

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to 99 Days ]

Central Contacts

• ABBVIE CALL CENTER
  844-663-3742
  [email protected]

Locations (2)

Find similar trials in Anaheim, CA

Related Studies

• A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
  PHASE1 · Recruiting · AbbVie · Cypress, California
• A First-in-Human Single and Multiple Ascending Dose Study of MT-201
  PHASE1 · Recruiting · Mirador Therapeutics, Inc. · San Diego, California
• An Investigational Study Examining the Cross-Validation of QbMobile in ADHD and Normative Populations
  Enrolling By Invitation · Qbtech AB · San Jose, California
• A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants
  PHASE1 · Recruiting · AbbVie · Grayslake, Illinois